Top Five Vaccine Companies in the World

Top five pharma companies in 2021 

The global pharmaceutical industry is predicted to witness positive growth because the top pharma companies are at forefront of the fight against COVID-19. Top pharma companies are currently that specialize in developing vaccine to fight COVID-19. Image courtesy of Dmitry Kalinovsky/Shutterstock. The global pharmaceutical industry is predicted to witness positive growth because the top pharma companies are at forefront of the fight against COVID-19. From Johnson & Johnson to Shanghai Pharmaceuticals, Pharmaceutical Technology lists the highest five pharmaceutical companies in 2021, supported revenues. 

 The world’s biggest pharmaceutical companies: Top five by revenue 

 1. Johnson & Johnson – $56.1bn

 2. Pfizer – $51.75bn

 3. Roche – $49.23bn 

 4. Novartis – $47.45bn

 5. Merck & Co. – $46.84bn

 1. Johnson & Johnson – $56.1bn

 Johnson & Johnson is currently involved in development of a vaccine to fight the COVID-19 disease. Image courtesy तु of Johnson & Johnson Services, Inc. Johnson & Johnson’s (J&J) consumer health segment recorded a 0.3% increase in revenues, majorly contributed by sales within the US market along side acquisitions and divestitures, which had a positive impact of 1.6% on sales growth. Revenues of the pharmaceutical division grew by 3.6%, driven by the immunology ($13.95bn) and oncology ($10.69bn) portfolio. a number of the new prescribed drugs approved during the year included BALVERSA™ (erdafitinib), XARELTO® (rivaroxaban), SPRAVATO® (esketamine), INVOKANA® (canagliflozin) and STELARA® (ustekinumab). J&J expects minor disruption to its pharmaceutical business in 2020 although growth is projected to stay above market growth. the bulk of the categories of the buyer health segment are anticipated to perform well, although certain categories could also be impacted thanks to reduced store visits and social distancing behaviours. J&J is functioning towards the event of a COVID-19 vaccine through the Ad26® vector technology and PER.C6® manufacturing platform. The vaccine candidate was announced in March 2020 and entered pre-manufacturing in June 2020. Clinical trials were commenced in September 2020 with data expected to be available in December 2020. supported the results, the primary batches of the vaccine are expected to be available within the half-moon of 2021 for emergency use. 

 2. Pfizer – $51.75bn  

The US contributed to 46% of Pfizer’s sales in 2019. Image courtesy of Michael Vi/Shutterstock. Pfizer recorded a forty five decline in revenues with the biopharma segment accounting for 76.2% of the revenues. International markets contributed to 54% of the company’s revenues that were driven by the sales of anti-infective products in China, including its antibiotic Sulperazon. The US accounted for the remaining 46% of the sales, which were affected thanks to the generic competition to anti-seizure drug Lyrica. The company formed a venture with GlaxoSmithKline (GSK) to mix their consumer healthcare businesses. Pfizer owns a 32% equity interest within the venture while GSK owns the rest . The Upjohn business segment was announced to be combined with Mylan to make a replacement drug company named Viatris. Pfizer acquired Array BioPharma and Therachon Holding for $11.2bn and $340m, respectively, additionally to AstraZeneca’s small molecule anti-infectives for $1bn. the corporate also acquired the licence for Akcea Therapeutics’ investigational antisense therapy ANGPTL3-LRx. Pfizer’s sales were impacted within the half-moon of 2020 thanks to the lockdown restrictions and a decline in patient visits. the corporate plans to extend investment in research and development by $500m towards the event of anti-infective products and a COVID-19 vaccine named BNT162 mRNA. Phase 2b/3 trials on the vaccine began in July 2020 while regulatory approval is predicted within the fourth quarter of 2020, supported the results. 

 3. Roche – $49.23bn  

Roche’s cobas® SARS-CoV-2 test is meant to be used under the FDA’s Emergency Use Authorization (EUA). Image courtesy of F. Hoffmann-La Roche Ltd. Revenues of Roche’s pharmaceutical division increased by 11% year-on-year, driven by sales of latest medicines, including Ocrevus, Hemlibra, Tecentriq, and Perjeta. Tecentriq within the oncology segment and Actemra/RoActemra and Esbriet in immunology also contributed significantly to the company’s revenues despite the negative performance of the biosimilars business in Europe and Japan. Competition from biosimilars particularly of MabThera/Rituxan, Herceptin and Avastin within the US impacted sales by $1.55bn. the corporate reported a 36% growth in China thanks to broader penetration , although the US remained the most important contributor to its sales, followed by Europe and Japan. A key transaction for the pharmaceutical division during the year was the acquisition of Spark Therapeutics for $4.8bn. The COVID-19 pandemic is predicted to possess a positive impact on Roche’s sales. The company’s oncology drugs Actemra/RoActemra are being investigated in clinical phase three trials to work out their safety and efficacy in treating severe COVID-19 pneumonia. Production capacity of the drugs is planned to be increased supported the results. 

 4. Novartis – $47.45bn

 Novartis partnered with several organisations for COVID-19 research and development activities. Image courtesy of Novartis AG. Novartis recorded a 6% year-on-year growth in 2019 revenues, with the innovative medicines division contributing 79% of the revenues and Sandoz accounting for the remaining 21%. Majority of the company’s revenues were contributed by established markets, including the US, Canada, Western Europe, Japan, Australia, and New Zealand. Key transactions completed in 2019 included the spin-off of the Alcon segment into a separate business, acquisition of the japanese business of Aspen Global Incorporated, and merger with The Medicines Company. Novartis also acquired Xiidra dry eye medication from Takeda. Key drugs approved in 2019 were Zolgensma for the treatment of spinal muscular atrophy in paediatric patients aged but two years, Beovu for the treatment of neovascular (wet) age-related degeneration , and Adakveo to scale back the frequency of vaso-occlusive crises in patients with red blood cell disease aged 16 years and older. Novartis expects manageable disruption to its operations thanks to the COVID-19 pandemic. the corporate has formed collaborations with variety of research organisations to develop a treatment for the coronavirus disease. it's initiated a phase three clinical test for testing the efficacy of its myelofibrosis drug ruxolitinib in treating pneumonia in COVID-19 patients, along side a phase three trial of hydroxychloroquine alone and together with azithromycin for the treatment of patients with COVID-19. 

 5. Merck & Co. – $46.84bn  

Ms reenues in 2019 were primarily driven by oncology, human health vaccines and animal health divisions. Image courtesy of Merck Sharp & ohmeCorp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. Merck & Co. reported an 11% year-on-year increase in revenues driven by oncology, human health vaccines, and animal health divisions. International sales, led by China, contributed a moderately higher percentage to the company’s revenues. Sales in China grew by 47%, driven by Keytruda and Gardasil/Gardasil 9. In 2019, Merck received approval for ERVEBO® (Ebola Zaire Vaccine, Live) for the prevention of disease caused by Zaire ebolavirus in individuals aged 18 years and older. RECARBRIO™ for sophisticated tract infections and ZERBAXA® for the treatment of pneumonia were other drugs approved within the year. the corporate also received approval for several indications for its oncology drug Keytruda as monotherapy, also as combination therapy for the treatment of varied sorts of cancer. The multiple approvals led to higher demand for the drug with global sales growing by 55%. Merck completed the acquisition of clinical-stage biopharmaceutical companies, including Peloton Therapeutics, Immune Design, and ArQule to strengthen its oncology portfolio. It also acquired Antelliq Group to strengthen its animal health business. Merck expects a revenue impact of $2.1bn in 2020 thanks to the unfavourable conditions created by the COVID-19 pandemic. It started recruitment for trails on its experimental COVID-19 vaccine candidate in September 2020. it's also collaborated with the Institute for Systems Biology and is a component of the NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV consortium) to develop vaccine and drug candidates against the disease.